Search results for "malattie"

showing 10 items of 1963 documents

Usefulness of microalbuminuria in cardiovascular risk stratification of essential hypertensive patients

2004

<i>Background/Aims:</i> To evaluate the influence of microalbuminuria (albumin excretion rate – AER) determination and echocardiography (ECHO) on cardiovascular risk stratification, initially performed according the 1999 WHO/ISH guidelines by using only routine diagnostic procedures with or without fundal examination. <i>Methods:</i> 312 essential hypertensives attending our institution were studied retrospectively. Cardiovascular risk was assessed in a semiquantitative way using four categories of absolute cardiovascular disease risk (low, medium, high and very high risk), as proposed by the 1999 WHO/ISH guidelines, on the basis of data on the average 10-year risk o…

MaleNephrologymedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesMicroalbuminuria. Cardiovascular risk. Left ventricular hypertrophy. Hypertension.Albumin excretion rateurologic and male genital diseasesLeft ventricular hypertrophyRisk AssessmentRetinaInternal medicinemedicineAlbuminuriaHumansRisk factorRetrospective StudiesSettore MED/14 - NefrologiaProteinuriabusiness.industryGeneral MedicineMiddle AgedPrognosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolarefemale genital diseases and pregnancy complicationsSurgeryOphthalmoscopyCardiovascular DiseasesEchocardiographyNephrologyHypertensionRisk stratificationCardiologyFemaleMicroalbuminuriamedicine.symptombusiness
researchProduct

Gastritis and gastroesophageal reflux disease are strongly associated with non-allergic nasal disorders

2021

AbstractBackgroundGastroesophageal reflux disease (GERD) has been reported to be significantly associated with chronic rhinosinusitis, but the strength of the association is still debated.AimsTo evaluate the strength of the association between gastritis/GERD and non-allergic rhinitis (NAR)/allergic rhinitis (AR)/sinusitis.MethodsWe investigated 2887 subjects aged 20–84 years, who underwent a clinical visit in seven Italian centres (Ancona, Palermo, Pavia, Terni, Sassari, Torino, Verona) within the study on Gene Environment Interactions in Respiratory Diseases, a population-based multicase-control study between 2008 and 2014. Subjects were asked if they had doctor-diagnosed “gastritis or sto…

MaleNon-allergic rhinitisGastroesophageal reflux diseaseGastroenterologyAllergic rhinitis0302 clinical medicinePrevalenceNon-allergic rhiniti030223 otorhinolaryngologySinusitisRhinitisAged 80 and overeducation.field_of_studyMiddle AgedGastrititItalyGastritisGastroesophageal RefluxFemalePublic HealthGastritismedicine.symptomResearch ArticleAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationGastrititsSettore MED/10 - Malattie Dell'Apparato RespiratorioNOHiatal herniaGastritits Gastroesophageal refux disease Allergic rhinitis Non-allergic rhinitis SinusitisYoung Adult03 medical and health sciencesAllergic rhinitis; Gastritits; Gastroesophageal reflux disease; Non-allergic rhinitis; SinusitisInternal medicineAllergic rhinitimedicineHumansGastroesophageal refux diseaseSinusitiseducationAgedlcsh:RC705-779business.industrylcsh:Diseases of the respiratory systemmedicine.diseaseRhinitis AllergicSinusitidigestive system diseases030228 respiratory systemRelative riskChronic DiseaseGERDAllergic rhinitis; Gastritits; Gastroesophageal reflux disease; Non-allergic rhinitis; Sinusitis Public HealthNon-allergic rhinitisbusinessEsophagitis
researchProduct

Early and mid-term effects of obstructive apneas in myocardial injury and inflammation.

2011

Abstract Background Obstructive sleep apnea (OSA) is associated with cardiovascular disorders, but the different comorbidities in OSA patients make it difficult to know their specific effects on the development of cardiovascular injury. The aim of the present study was to investigate whether recurrent obstructive apneas could lead to myocardial injury. Methods Thirty-six male Sprague–Dawley rats (300–350 g) were either acutely (3 h) or sustainably (5 h/day, for 10 days) subjected to obstructive apneas with a pattern of 15 s each, 60 apneas/h. Corresponding control groups were formed for the acute and sustained models. To assess the induction of systemic inflammation, IL1-β was measured in p…

MaleObstructive sleep apnea Myocardial injury Inflammation Animal modelsmedicine.medical_specialtyPathologyHeart diseaseHeart DiseasesInterleukin-1betaInflammationApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioSystemic inflammationRats Sprague-DawleyInternal medicinemedicineAnimalsInflammationSleep Apnea Obstructivebusiness.industryMyocardiumSleep apneaGeneral Medicinemedicine.diseaseRatsObstructive sleep apneaDisease Models AnimalApoptosisInitial phaseAcute DiseaseCardiologyDisease ProgressionCardiovascular Injurymedicine.symptombusinessSleep medicine
researchProduct

Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life

2020

Background: Mepolizumab (MEP) has been recently introduced to treat severe eosinophilic asthma. Trials have demonstrated a significant effectiveness in this asthma phenotype. We evaluated MEP efficacy on lung function, symptoms, asthma exacerbations, biologic markers, steroid dependence and controller treatment level in real-life. Methods: We retrospectively analyzed 134 severe asthmatics (61 males; mean age 58.3 ± 11; mean FEV1%:72 ± 21), treated with MEP for at least 6 months (mean duration:10.9 ± 3.7 months). Results: FEV1% improved significantly after MEP. Mean FEF25-75 also increased from 37.4 ± 25.4% to 47.2 ± 27.2% (p < 0.0001). Mean baseline blood eosinophil level was 712 ± 731/μ…

MaleOmalizumabFEF(25-75)step-down0302 clinical medicineMaintenance therapyAdrenal Cortex HormonesSettore MED/10Pharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicinesmall airwaysAsthma exacerbationsmepolizumabMiddle AgedAnesthesiaFEF25-75CorticosteroidDrug Therapy CombinationFemalemedicine.drugPulmonary and Respiratory Medicinesevere asthmamedicine.drug_classMepolizumab Severe asthma Real-life Small airways FEF25-75 Oral corticosteroids Step-down EffectiveneseffectivenessSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroidsAntibodies Monoclonal HumanizedNO03 medical and health sciencesEffectiveness FEF 25-75 Mepolizumab Oral corticosteroids Real-life Severe asthma Small airways Step-downmedicineHumansIn real lifeFEFreal-lifeAgedRetrospective StudiesBiologic markerbusiness.industryEffectivenesBiochemistry (medical)Effectiveness; FEF; 25-75; Mepolizumab; Oral corticosteroids; Real-life; Severe asthma; Small airways; Step-downAirway obstructionmedicine.diseaseAsthmaBlood Cell Countrespiratory tract diseasesAirway ObstructionEosinophils030228 respiratory systemeffectiveness; FEF(25-75); mepolizumab; oral corticosteroids; real-life; severe asthma; small airways; step-down25-75businessMepolizumab
researchProduct

Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide

2015

Treatment of acute promyelocytic leukaemia (APL) with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) is highly effective first-line therapy, although approximately 5-10% of patients relapse. Tamibarotene is a synthetic retinoid with activity in APL patients who relapse after chemotherapy and ATRA, but has not been studied in relapse after treatment with ATO and ATRA. We report on a phase II study of tamibarotene in adult patients with relapsed or refractory APL after treatment with ATRA and ATO (n = 14). Participants were treated with tamibarotene (6 mg/m(2) /d) during induction and for up to six cycles of consolidation. The overall response rate was 64% (n = 9), the rate of comp…

MaleOncogene Proteins Fusionmedicine.medical_treatmentDrug ResistancePhases of clinical researchSalvage therapyKaplan-Meier EstimatePharmacologyGastroenterologyBenzoatesArsenicalschemistry.chemical_compoundLeukemia Promyelocytic AcuteRecurrenceAntineoplastic Combined Chemotherapy ProtocolsMedicineArsenic trioxidePromyelocyticOncogene ProteinsTumorLeukemiaRemission InductionHematopoietic Stem Cell TransplantationCell DifferentiationOxidesclinical trialHematologyMiddle AgedCombined Modality Therapyall-trans retinoic acidarsenic trioxideLeukemiaCardiovascular DiseasesFemalemedicine.drugAdultmedicine.medical_specialtyTetrahydronaphthalenesAcute promyelocytic leukaemia; all-trans retinoic acid; arsenic trioxide; clinical trial; tamibarotene; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Benzoates; Biomarkers Tumor; Cardiovascular Diseases; Cell Differentiation; Combined Modality Therapy; Consolidation Chemotherapy; Disease-Free Survival; Drug Resistance Neoplasm; Febrile Neutropenia; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia Promyelocytic Acute; Male; Middle Aged; Oncogene Proteins Fusion; Oxides; Recurrence; Remission Induction; Salvage Therapy; Tetrahydronaphthalenes; TretinoinAntineoplastic AgentsTretinoinAcuteArticleDisease-Free SurvivalTretinoinInternal medicineBiomarkers TumorHumansFusionneoplasmsAgedFebrile NeutropeniaSalvage TherapyChemotherapybusiness.industrymedicine.diseasetamibaroteneAcute promyelocytic leukaemiaConsolidation ChemotherapychemistryDrug Resistance NeoplasmNeoplasmTamibarotenebusinessSettore MED/15 - Malattie del SangueFebrile neutropeniaBiomarkers
researchProduct

Osteonecrosis of the jaw (ONJ) in renal cell cancer patients after treatment including zoledronic acid or denosumab.

2014

Dear Editor, The paper by Henry et al. published by Supportive Care in Cancer comparing efficacy of denosumab versus zoledronic acid in patients with bone metastases of advanced solid tumours [1] comes to integrate the original reports of three pivotal large randomized phase 3 trials [2–4], the publication by Saad et al. about osteonecrosis of the jaw (ONJ) in those three trials [5], and the combined outcome analysis by Lipton et al. [6]. Henry et al. [1] reported outcomes of the single trial conducted on patients with solid tumours (except breast or prostate cancers, object of other two trials) [2, 3], excluding patients with multiple myeloma: This ad hoc analysis confirmed the superiority…

MaleOncologymedicine.medical_specialtyBevacizumabONJ renal cell cancerBone NeoplasmsAntibodies Monoclonal HumanizedPazopanibSettore MED/28 - Malattie OdontostomatologicheNeoplasmsInternal medicinemedicineHumansBone ResorptionEverolimusBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryImidazolesmedicine.diseaseTemsirolimusZoledronic acidDenosumabOncologyFemalebusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report

2012

Abstract Background Primary myelofibrosis is a myeloproliferative disorder characterized by bone marrow fibrosis, abnormal cytokine expression, splenomegaly and anemia. The activation of JAK2 and the increased levels of circulating proinflammatory cytokines seem to play an important role in the pathogenesis of myelofibrosis. Novel therapeutic agents targeting JAKs have been developed for the treatment of myeloproliferative disorders. Ruxolitinib (INCB018424) is the most recent among them. Case presentation To our knowledge, there is no evidence from clinical trials of an increased risk of tuberculosis during treatment with JAK inhibitors. Here we describe the first case of tuberculosis in a…

MaleOncologymedicine.medical_specialtyRuxolitinibTuberculosisSettore MED/17 - Malattie InfettiveAnemiaAntitubercular AgentsMyelofibrosislcsh:MedicineCase ReportGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineMyeloproliferative DisordersInternal medicineNitrilesmedicineHumansTuberculosisMyelofibrosislcsh:Science (General)lcsh:QH301-705.5Medicine(all)Janus kinase 2biologyLatent tuberculosisBiochemistry Genetics and Molecular Biology(all)business.industryTuberculosis Myelofibrosis Ruxolitiniblcsh:RGeneral MedicineJanus Kinase 2medicine.diseasePyrimidinesRuxolitiniblcsh:Biology (General)Primary MyelofibrosisImmunologybiology.proteinPyrazolesbusinessmedicine.druglcsh:Q1-390BMC Research Notes
researchProduct

Evaluation of effectiveness of photobiostimulation in alleviating side effects after dental implant surgery. A randomized clinical trial

2020

Background To assess if photobiostimulation (PBS) alleviates pain intensity/duration and swelling after implant surgery. Material and Methods Sixty subjects (27 male and 33 female, with a mean age of 47,13 8.05 years) were included and randomly assigned to experimental group (implant surgery and photobiostimulation), placebo group (implant surgery and simulated photobiostimulation) and control group (implant surgery only). Inclusion criteria: subjects older than 20 years, with a healthy oral mucosa and requiring implant surgery. Exclusion criteria: pregnancy, history of implant failure, light sensitivity, metabolic deseases, consumption of antibiotics or corticosteroids in the last two week…

MaleOral Surgical ProceduresAnalgesicCirurgia dentalPainPlaceboPhotobiostimulationImplant surgerylaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled trialInterquartile rangelawmedicineHumansOral mucosaGeneral DentistryAged 80 and overDental ImplantsLLLT photobiostimulation pain implant surgery.AnalgesicsPain PostoperativePregnancyImplants dentalsbusiness.industryLLLTResearchDental implantsImplant failureMED/28 - MALATTIE ODONTOSTOMATOLOGICHE030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]Photobiologymedicine.anatomical_structureFotobiologiaOtorhinolaryngologyAnesthesiaDental surgeryUNESCO::CIENCIAS MÉDICASFemaleSurgeryAnalysis of varianceLLLT Photobiostimulation Pain Implant surgerybusinessImplantology
researchProduct

Marshall's vein persistence: A rare and occasional finding during pacemaker implantation

2012

In adults the oblique vein of Marshall is usually absent or very thin, and it is hard to be found. In this case report we describe a case of persistence observed during pacemaker implantation.

MalePacemaker ArtificialVena Cava SuperiorSettore MED/09 - Medicina InternaHumansPhlebographyMiddle AgedAtrioventricular BlockSettore MED/11 - Malattie Dell'Apparato CardiovascolareMARSHALL’S VEIN PERSISTENCE PACEMAKER IMPLANTATION
researchProduct

Scalp eschar and neck lymphadenopathy caused by Rickettsia massiliae

2013

To the Editor: Scalp eschar and neck lymphadenopathy is a common clinical entity that most frequently affects women and children during spring and fall. It is usually caused by Rickettsia slovaca and R. raoultii. Typical clinical signs are a scalp lesion at the tick bite site and regional, often painful, lymphadenopathy. Acute disease can be followed by residual alopecia at the bite site (1,2). Two designations have been proposed for this syndrome: tick-borne lymphadenopathy and Dermacentor-borne necrosis-erythema-lymphadenopathy (both have been associated with R. slovaca); however, the most generic and all-inclusive term is scalp eschar and neck lymphadenopathy. R. massiliae belongs to the…

MalePathologyLetterEpidemiologylcsh:MedicineSerologyMedicineRickettsiaRickettsia massiliaebacteriafeverbiologyRickettsia InfectiontickInfectious Diseasesmedicine.anatomical_structuremedicine.symptomDermacentorHumanDNA BacterialMicrobiology (medical)medicine.medical_specialtyAdolescentSettore MED/17 - Malattie InfettiveMolecular Sequence DataInfectious DiseaseEscharTicklcsh:Infectious and parasitic diseasesCicatrixBacterial Typing Techniquelymphadenopathylcsh:RC109-216Rickettsia; Rickettsia massiliae; bacteria; eschar; fever; lymphadenopathy; scalp eschar and neck lymphadenopathy; tick; Adolescent; Alopecia; Animals; Bacterial Typing Techniques; Base Sequence; Cicatrix; DNA Bacterial; Dermacentor; Humans; Lymphatic Diseases; Male; Molecular Sequence Data; Rickettsia; Rickettsia Infections; Scalp; Microbiology (medical); Infectious Diseases; EpidemiologyLetters to the EditorDermacentorRickettsia massiliaeScalpScalp EscharBase Sequencebusiness.industryAnimallcsh:RRickettsia massiliae; Scalp Eschar; LymphadenopathyAlopeciascalp eschar and neck lymphadenopathybiology.organism_classificationSpotted feverRickettsiaScalpLymphatic Diseasebusinesseschar
researchProduct